Buying vaccine biotech Dynavax was an easy choice for Sanofi despite antivaccine moves by the Trump administration.
Sanofi Chief Executive Paul Hudson said on Wednesday the company is likely to see some weakness in U.S. vaccine demand this ...
Ocular Therapeutix shares are trading higher Thursday after reports suggested Sanofi is preparing a revised bid for the ...
With a White House drug pricing deal done and dusted and the threat of tariffs ameliorated, Sanofi is enjoying more clarity from the U.S. government now than the same time last year. But several ...
Sanofi's CEO Paul Hudson highlights a potential dip in U.S. vaccine demand due to misinformation and policy changes under the ...
Sanofi chief executive Paul Hudson said on Wednesday the U.S. is likely to see a slight weakness in vaccine demand this year ...
Sanofi CEO Paul Hudson reports a decline in U.S. vaccine demand due to misinformation and policy changes from the Trump ...
Incoming PhRMA Chair Paul Hudson, a day before the White House announcement, pledged to work with the administration as the ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
Sanofi (SAN:CA) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM ESTCompany ParticipantsPaul Hudson - CEO & ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback